HUTCHMED (CHINA) LIMITED - AMERICAN DEPOSITARY SHA

HUTCHMED to Attend Upcoming Investor Conferences

07 May 2021 06:00:00 By Nasdaq GlobeNewswire

Change of Company Name

04 May 2021 02:00:00 By Nasdaq GlobeNewswire

HUTCHMED Completes Rolling Submission of NDA to U.S. FDA for Surufatinib for the Treatment of Advanced Neuroendocrine Tumors

03 May 2021 06:00:00 By Nasdaq GlobeNewswire

HUTCHMED Announces US$100 Million Equity Investment by Baring Private Equity Asia

08 Apr 2021 02:30:00 By Nasdaq GlobeNewswire

HUTCHMED Initiates International Phase I Trials of IDH1/2 Dual Inhibitor in Patients with Advanced Solid Tumors or Hematological Malignancies

29 Mar 2021 01:00:00 By Nasdaq GlobeNewswire

HUTCHMED Enters Agreement to Divest Non-Core OTC Joint Venture for US$169 Million

24 Mar 2021 08:30:00 By Nasdaq GlobeNewswire

HUTCHMED Initiates a Phase Ib/II Trial of Surufatinib in Combination with Tislelizumab in Patients with Advanced Solid Tumors

24 Mar 2021 02:00:00 By Nasdaq GlobeNewswire

Hutchison China MediTech Limited Reports 2020 Full Year Results and Provides Business Updates and Evolves Corporate Identity

04 Mar 2021 06:00:02 By Nasdaq GlobeNewswire

Chi-Med to Announce 2020 Final Results

03 Feb 2021 01:00:00 By Nasdaq GlobeNewswire

Chi-Med Highlights Savolitinib Clinical Data to be Presented at Virtual WCLC

14 Jan 2021 04:00:00 By Nasdaq GlobeNewswire